Critical Care - RESEARCH & PRODUCTS - 尊龙凯时生物

    尊龙凯时

    Quality Products
    RESEARCH & PRODUCTS

    Scroll down


    According to the China Food and Drug Administration regulation No. 24, which announced the "Drug Instruction and Labeling Regulations", after the drug instruction is approved for revision, the drug manufacturer shall immediately notify the relevant drug business enterprises, user units and other departments of the revised content. In order to enable the relevant units and medical & health professionals to obtain the latest information on the instructions in a timely manner, our company is required to publish the latest approved information on the instructions.

     (Only listed products in mainland China)


    公司地址：这里是公司地址后期需要替换设计占位后台可替换

    企业邮箱：infu@singlera.com.cn

    联系电话：+86-8888-8888

    商务联系：BD@singlera.com.cn

    人力资源：HR@singlera.com.cn

    For Health Care Professionals Only

    • Click “YES” if you are a health

      care practitioner

      YES ＞

    • Click “CANCEL” if you are NOT

      a health care practitioner

      CANCEL ＞
    友情链接: